Arrowhead Pharmaceuticals, Inc.
ARWR
$55.05
$0.040.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.95% | 823.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.95% | 823.66% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 2.95% | 823.66% | |||
| SG&A Expenses | 58.82% | -16.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.11% | 9.85% | |||
| Operating Income | -7.48% | 126.64% | |||
| Income Before Tax | -21.73% | 120.17% | |||
| Income Tax Expenses | -99.86% | 4,676.66% | |||
| Earnings from Continuing Operations | 75.19% | 109.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 106.44% | -1,268.89% | |||
| Net Income | 229.73% | 86.45% | |||
| EBIT | -7.48% | 126.64% | |||
| EBITDA | -6.52% | 131.69% | |||
| EPS Basic | 230.47% | 86.33% | |||
| Normalized Basic EPS | 217.78% | 83.93% | |||
| EPS Diluted | 226.36% | 86.19% | |||
| Normalized Diluted EPS | 214.67% | 83.93% | |||
| Average Basic Shares Outstanding | -0.61% | -0.84% | |||
| Average Diluted Shares Outstanding | 2.05% | -0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||